<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: High mobility group (HMG) non-<z:chebi fb="0" ids="15358">histone</z:chebi> chromosomal proteins HMG1 and HMG2 have been identified as novel antigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-<z:chebi fb="0" ids="34507">ANCAs</z:chebi>), and the existence of anti-HMG1 and anti-HMG2 antibodies in a population of patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> has been reported </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: To investigate whether HMG1 and HMG2 are target antigens for p-<z:chebi fb="0" ids="34507">ANCAs</z:chebi> in autoimmune <z:hpo ids='HP_0012115'>hepatitis</z:hpo> (AIH) </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS: Serum samples from 28 patients with AIH, 44 patients with primary <z:hpo ids='HP_0002613'>biliary cirrhosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>), 27 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C, and 23 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B were tested </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:chebi fb="0" ids="34507">ANCAs</z:chebi> were detected by routine indirect immunofluorescence (IIF) </plain></SENT>
<SENT sid="4" pm="."><plain>Anti-HMG1 and anti-HMG2 antibodies were assayed by enzyme linked immunosorbent assay </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: p-<z:chebi fb="0" ids="34507">ANCAs</z:chebi> were detected in 89% (25/28) of patients with AIH, 36% (16/44) of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>, 11% (3/27) of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C, and 13% (3/23) of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B </plain></SENT>
<SENT sid="6" pm="."><plain>Anti-HMG1 and/or anti-HMG2 antibodies were detected in 89% (25/28) of patients with AIH, 70% (31/44) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>, 26% (7/27) with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C, and 9% (2/23) with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B </plain></SENT>
<SENT sid="7" pm="."><plain>In AIH, anti-HMG1 and/or anti-HMG2 antibodies were detected in 96% (24/25) of p-<z:chebi fb="0" ids="34507">ANCA</z:chebi> positive patients </plain></SENT>
<SENT sid="8" pm="."><plain>The p-<z:chebi fb="0" ids="34507">ANCA</z:chebi> staining pattern detected by IIF using sera from patients with AIH disappeared or decreased in titre after preincubation with a mixture of HMG1/HMG2 </plain></SENT>
<SENT sid="9" pm="."><plain>The presence and titres of those antibodies in AIH correlated significantly with those of p-<z:chebi fb="0" ids="34507">ANCA</z:chebi>, but not with those of anti-nuclear antibody or anti-smooth muscle antibody </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: HMG1 and HMG2 are significant target antigens of p-<z:chebi fb="0" ids="34507">ANCA</z:chebi> in AIH </plain></SENT>
</text></document>